Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose, Inc. (NASDAQ: OPTN) is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. News related to Optinose often centers on its commercial product XHANCE, financial performance, clinical data, and corporate developments. The company reports net product revenue from sales of XHANCE and provides regular updates on prescription trends, including new prescriptions and total prescriptions, as well as commentary on inflection points in demand.
Investors and observers following OPTN news can expect recurring announcements of quarterly and full-year financial results, including net revenue from XHANCE, operating expenses, income or loss from operations, and balance sheet data such as cash and cash equivalents. Optinose also issues guidance on expected net revenue, average net revenue per prescription, and operating expenses, and may update this guidance based on evolving business conditions.
Beyond financial updates, Optinose news includes clinical and scientific developments. The company has highlighted peer-reviewed publications describing the efficacy of XHANCE, including randomized controlled trials in chronic rhinosinusitis patients with or without prior sinus surgery. These communications discuss outcomes such as symptom improvement, sinus opacification, and quality of life.
Corporate and capital markets news for OPTN includes announcements such as a 1-for-15 reverse stock split intended to help regain compliance with Nasdaq’s minimum bid price requirement, as well as leadership changes and appointments. Optinose has also announced that it has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and customary closing conditions. For those tracking OPTN, the news flow provides insight into the company’s commercial trajectory, financial condition, clinical positioning of XHANCE, and potential future corporate structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on ENT and allergy patients, announced the granting of non-qualified stock option awards for 54,000 shares to three new employees on April 17, 2023. The stock options, granted outside of the 2010 Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $2.05, matching the closing stock price on the grant date. The options have a 10-year term and will vest over four years, with one-fourth vesting on the first anniversary and the rest in monthly installments, contingent on continued service with the company.
Optinose (NASDAQ:OPTN) has announced that its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023, at 3:45 p.m. ET. Interested parties can tune in to the live webcast through the Investors page of the Optinose website. A replay of the presentation will be accessible for 30 days post-event.
Optinose specializes in providing treatments for patients attended to by ear, nose, and throat (ENT) and allergy specialists. The company aims to address specific needs within this domain. For further details, visit www.optinose.com or follow them on social media platforms such as Twitter and LinkedIn.
Optinose (NASDAQ:OPTN) reported net revenues of $20.9 million for Q4 2022, down 7% from the previous year, and $76.3 million for the full year, marking a 4% increase. The decline in Q4 revenues is attributed to fewer prescriptions for XHANCE. The company recently submitted an sNDA to the FDA for a new indication of XHANCE as a treatment for chronic rhinosinusitis, expecting a decision by May 2023. For 2023, Optinose forecasts total revenues from XHANCE to be $62 million to $68 million, with reductions in operating expenses by approximately $30 million.
Optinose (NASDAQ:OPTN) announced that it will report its fourth quarter 2022 financial results and corporate updates on March 7, 2023, before market open. The company, which focuses on patients treated by ENT and allergy specialists, will host a conference call at 8:00 a.m. Eastern Time on the same day. Participants can access the call via a webcast on the company’s website or join by telephone after prior registration. A replay of the event will be available for 60 days following its conclusion.